Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fujifilm Toyama Chemical’s T-817MA Enters PII to Examine Post-Stroke Rehabilitation Enhancement Effects
June 7, 2019
- Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019
- Merck SVP Roy Baynes Recounts Keytruda Development, Says We Followed Science
June 6, 2019
- Japan Fair Trade Watchdog Issues Cease and Desist and Surcharge Payment Orders to Koa Isei for Price Fixing
June 6, 2019
- Otsuka Chemical Acquires Cefixime-Related Business from Astellas
June 6, 2019
- Fujifilm Develops Continuous Production System for Biologics, Set to Begin Contract Manufacturing in 2020
June 6, 2019
- Fujifilm Invests 200 Million Yen in Cell Therapy Startup
June 5, 2019
- Xofluza Hits Goal of Preventing Flu Onset in Japan PIII: Shionogi
June 5, 2019
- Astellas’s ADC Enfortumab Vedotin Logs 44% ORR in Advanced Urothelial Cancer in PII
June 5, 2019
- Amazon Web Services to Enhance Services for Healthcare Industry in Japan
June 5, 2019
- Takeda’s Takhzyro Reduces HAE Attacks in Initial Phase of Treatment
June 5, 2019
- No Japanese Enrolled, but AstraZeneca to Discuss Lynparza’s Pancreatic Cancer Data with PMDA: Oncology Chief
June 4, 2019
- Alecensa Slashes Progression Risk by 63% vs. Xalkori in Frontline NSCLC
June 4, 2019
- Lumicef Now in Japan PIII for Systemic Sclerosis: Kyowa Kirin
June 4, 2019
- Alecensa Filed in Japan for Rare Lymphoma: Chugai
June 4, 2019
- Rakuten Medical’s Photoimmunotherapy Demonstrates Favorable Tolerability in PIIa
June 4, 2019
- ASKA to Transfer Menoaid Hot Flash Drug to Hisamitsu
June 4, 2019
- Daiichi Sankyo’s ADC U3-1402 Shows Tumor Reduction in NSCLC Patients: Preliminary PI Data
June 4, 2019
- Takeda Pledges 1 Billion Yen in Global Fund, 2nd Investment in Fighting for HIV, TB, and Malaria
June 4, 2019
- Chugai’s Gene Mutation Analysis Program Now Available in Japan
June 4, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…